Radiopharm Theranostics Limited
RDPTF
$0.0113
$0.01051,312.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -74.08% | -73.48% | -221.84% | -218.84% | 1.49% |
| Total Revenue | -40.05% | -38.65% | -206.70% | -204.06% | -5.48% |
| Cost of Revenue | 0.70% | 3.06% | -42.04% | -43.47% | 76.94% |
| Gross Profit | -15.72% | -18.42% | 6.89% | 9.19% | -160.67% |
| SG&A Expenses | -12.43% | -10.37% | -10.35% | -12.56% | 16.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.86% | -1.61% | -28.35% | -30.12% | 49.72% |
| Operating Income | -3.86% | -6.29% | 8.55% | 10.81% | -71.01% |
| Income Before Tax | 20.98% | 19.13% | -3.41% | -0.86% | -95.85% |
| Income Tax Expenses | 222.55% | 231.37% | 2,250.00% | 2,240.00% | -24.44% |
| Earnings from Continuing Operations | 20.67% | 18.82% | -3.71% | -1.15% | -95.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.54% | -13.58% | -- | -- | -- |
| Net Income | 20.90% | 19.06% | -3.71% | -1.15% | -86.88% |
| EBIT | -3.86% | -6.29% | 8.55% | 10.81% | -71.01% |
| EBITDA | -4.51% | -6.95% | 8.71% | 10.96% | -84.38% |
| EPS Basic | 85.96% | 85.59% | 19.09% | 21.33% | -57.72% |
| Normalized Basic EPS | 81.31% | 81.31% | 47.52% | 49.04% | -15.05% |
| EPS Diluted | 85.96% | 85.59% | 19.09% | 21.33% | -57.72% |
| Normalized Diluted EPS | 81.31% | 81.31% | 47.52% | 49.04% | -15.05% |
| Average Basic Shares Outstanding | 459.16% | 459.16% | 28.24% | 28.24% | 18.68% |
| Average Diluted Shares Outstanding | 459.16% | 459.16% | 28.24% | 28.24% | 18.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
